Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€103.36

€103.36

-0.060%
-0.06
-0.060%
€179.17
 
11:42 / Tradegate WKN: A1KBYX / Symbol: ZTS / Name: Zoetis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Zoetis Inc. A Stock

With only a change of -€0.060 (-0.060%) the Zoetis Inc. A price is nearly unchanged from yesterday.
Zoetis Inc. A is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 179 € there is a hugely positive potential of 73.18% for Zoetis Inc. A compared to the current price of 103.36 €.
So far the community has only identified positive things for Zoetis Inc. A stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Zoetis Inc. A in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Zoetis Inc. A vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Zoetis Inc. A -0.060% -6.862% -4.629% -37.975% -34.027% -30.813% -20.593%
Johnson & Johnson -0.210% -2.304% 6.832% 21.509% 25.022% 2.379% 40.294%
Elanco Animal Health Inc. -0.860% -6.060% -3.683% 61.966% 63.509% 50.839% -22.072%
Biogen Inc. -0.640% -0.096% 20.131% 2.089% 8.539% -44.908% -22.847%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-04

When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.

Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.

EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.

Comments

Prediction Buy
Perf. (%) -2.83%
Target price 137.488
Change
Ends at 03.12.26

Zoetis (NYSE:ZTS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $160.00 price target on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.01%
Target price 138.208
Change
Ends at 12.11.26

Zoetis (NYSE:ZTS) had its price target lowered by analysts at BTIG Research from $200.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -0.06%
Target price 151.410
Change
Ends at 10.11.26

Zoetis (NYSE:ZTS) had its price target lowered by analysts at Morgan Stanley from $211.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

News

2 Stocks to Buy Near Their 52-Week Lows: https://g.foolcdn.com/editorial/images/844124/person-using-a-smartphone.jpg
2 Stocks to Buy Near Their 52-Week Lows

Recent developments have led to significant declines in the stock prices of Pinterest (NYSE: PINS) and Zoetis (NYSE: ZTS). Due to company-specific issues, both are currently not that far from their

Zoetis: A Solid Investment in the Growing Pet Medicine Market?: https://g.foolcdn.com/editorial/images/835280/thumb-8.jpg
Zoetis: A Solid Investment in the Growing Pet Medicine Market?

Explore the exciting world of Zoetis (NYSE: ZTS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today

Ah, 10 years ago. It was 2015, and selfie sticks and hoverboards were all over. Apple debuted its Apple Watch to much fanfare, and...perhaps you invested in shares of Zoetis (NYSE: ZTS) stock? If